"About 25 percent of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations."
https://news.mit.edu/2026/lung-cancers-can-use-two-different-mechanisms-evade-kras-inhibiting-drugs-0930?utm_source=join1440&utm_medium=email&utm_placement=newsletter&user_id=66c4c92f5d78644b3ac5d5b4
No comments:
Post a Comment